PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
69.20
ESG score 1.1-1.2x Biotechnology median of 58.57. Philip Fisher would examine if superior ESG practices support long-term growth and stakeholder loyalty.
70.45
Environmental score exceeding 1.2x Biotechnology median of 54.84. Joel Greenblatt would verify if this climate leadership creates pricing power and regulatory advantages.
70.37
Social score 1.1-1.2x Biotechnology median of 60.55. Philip Fisher would examine if superior social practices support talent retention and brand strength.
66.79
Governance score 1.1-1.2x Biotechnology median of 60.84. Philip Fisher would examine if superior governance practices support long-term value creation.